SYDNEY, April 19, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce that it has entered into a worldwide exclusive licensing agreement and a master services agreement with Evotec SE (FRA: EVT), a leading European drug discovery and development company, for...
Small Business Restructuring (SBR) appointments have tripled in the first half of the 2025 financial year¹, revealing both growing awareness of th...
Adyen, the financial technology platform of choice for leading companies, today announced its expanded partnership with Temu, the global e-commerc...
Sydney, Australia – 1st April, 2025: Blend AI, a leading Australian adtech company, has announced the opening of its first US office in Austin, Te...
Workplace wellbeing has finally reached the mainstream. It’s no longer seen as a ‘nice to have’ or an afterthought—it’s a core business issue. But d...
Industry heavyweights join Samsara Eco to accelerate its enzymatic recycling technology Chief Innovation Officer and Executive Product Director a...
The National Print Awards (NPAs) are proud to introduce the Ricoh Women in Industry Award, a prestigious new accolade recognising and celebrating ...
